Vivimed Labs Standalone December 2023 Net Sales at Rs 37.14 crore, down 26.55% Y-o-Y

February 16, 2024 / 11:57 AM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Reported Standalone quarterly numbers for Vivimed Labs are:Net Sales at Rs 37.14 crore in December 2023 down 26.55% from Rs. 50.56 crore in December 2022.
Quarterly Net Loss at Rs. 16.17 crore in December 2023 up 15.44% from Rs. 19.12 crore in December 2022.
EBITDA stands at Rs. 0.92 crore in December 2023 up 114.94% from Rs. 6.16 crore in December 2022.Vivimed Labs shares closed at 4.95 on July 31, 2023 (NSE) and has given -52.40% returns over the last 12 months.
Vivimed Labs
Standalone Quarterly Resultsin Rs. Cr.
Dec'23Sep'23Dec'22
Net Sales/Income from operations37.1430.2850.56
Other Operating Income------
Total Income From Operations37.1430.2850.56
EXPENDITURE
Consumption of Raw Materials19.7616.9934.12
Purchase of Traded Goods------
Increase/Decrease in Stocks0.310.381.45
Power & Fuel------
Employees Cost8.598.598.44
Depreciation4.494.493.80
Excise Duty------
Admin. And Selling Expenses------
R & D Expenses------
Provisions And Contingencies------
Exp. Capitalised------
Other Expenses7.599.7312.71
P/L Before Other Inc. , Int., Excpt. Items & Tax-3.60-9.89-9.97
Other Income0.042.160.01
P/L Before Int., Excpt. Items & Tax-3.57-7.74-9.96
Interest13.1611.829.16
P/L Before Exceptional Items & Tax-16.72-19.56-19.12
Exceptional Items------
P/L Before Tax-16.72-19.56-19.12
Tax-0.55----
P/L After Tax from Ordinary Activities-16.17-19.56-19.12
Prior Year Adjustments------
Extra Ordinary Items------
Net Profit/(Loss) For the Period-16.17-19.56-19.12
Equity Share Capital16.5816.5816.58
Reserves Excluding Revaluation Reserves------
Equity Dividend Rate (%)------
EPS Before Extra Ordinary
Basic EPS-1.25-2.36-0.22
Diluted EPS-1.22-2.29-0.23
EPS After Extra Ordinary
Basic EPS-1.25-2.36-0.22
Diluted EPS-1.22-2.29-0.23
Public Share Holding
No Of Shares (Crores)------
Share Holding (%)------
Promoters and Promoter Group Shareholding
a) Pledged/Encumbered
- Number of shares (Crores)------
- Per. of shares (as a % of the total sh. of prom. and promoter group)------
- Per. of shares (as a % of the total Share Cap. of the company)------
b) Non-encumbered
- Number of shares (Crores)------
- Per. of shares (as a % of the total sh. of prom. and promoter group)------
- Per. of shares (as a % of the total Share Cap. of the company)------
Source : Dion Global Solutions Limited

Tags: #Earnings First-Cut #Pharmaceuticals #Results #Vivimed Labs
first published: Feb 16, 2024 11:44 am

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!